Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Renata Ortiz Pedrini is active.

Publication


Featured researches published by Renata Ortiz Pedrini.


Clinica Chimica Acta | 2008

Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study.

Eduardo Guimarães Camargo; Renata Ortiz Pedrini; Jorge Luiz Gross; Joiza Lins Camargo; Sandra Pinho Silveiro

Remarkable clinical trials, like the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS), have established that HbA1c is the cornerstone to predict the development of chronic vascular complications in diabetic subjects [1,2]. The American Diabetes Association (ADA) recommends HbA1c measurements at least twice a year, with target levels b7% [3]. However, it should be taken into account that many factors can influence the results, such as the analytical interference of some drugs, like aspirin (acetylsalicylic acid) [4–6]. This is an important issue, because low-dose aspirin is recommended for both primary and secondary cardiovascular disease prevention in diabetic patients [3]. Some in vitro and in vivo studies have suggested a potential interference of aspirin in HbA1c assays, especially in those that rely on the change of charge, like ion-exchange HPLC and electrophoresis [6–8]. Aspirin induces an acetylation of hemoglobin, giving it a negative charge and consequently increasing HbA1c levels in chromatographic assays [9]. There are no randomized clinical trials analyzing the possible effects of the antiplatelet agent on HbA1c values measured by ionexchange HPLC assay in diabetic patients. Therefore, the aim of this study was to evaluate the influence of low-dose aspirin on HbA1c levels measured by this method in type 2 diabetic patients. In this randomized, crossover, double-blind, placebocontrolled study, 14 type 2 DM patients received aspirin (300 mg/d) or an identical placebo for 8 weeks, with a 6week washout period. All patients signed a written informed consent approved by the Ethics Committee of the Hospital. The sample size calculation disclosed that a minimum of 12 patients was needed to detect an absolute change in HbA1c N0.5% (α=0.05 and β=0.20). The patients entered a run-in phase of 8 weeks, to stabilize metabolic control. All patients, except for 2 who received only insulin, used metformin, either alone or in combination


Clinical & Biomedical Research | 2008

Diagnosis, risk factors and pathogenesis of preeclampsia

Rafael Bueno Orcy; Renata Ortiz Pedrini; Pedro Salomão Piccinini; Sabrina Schroeder; Sérgio Hofmeister Martins-Costa; José Geraldo Lopes Ramos; Edison Capp; Helena von Eye Corleta


Rev. HCPA & Fac. Med. Univ. Fed. Rio Gd. do Sul | 2007

Diagnóstico, fatores de risco e patogênese da pré-eclâmpsia

Rafael Bueno Orcy; Renata Ortiz Pedrini; Pedro Salomão Piccinini; Sabrina Schroeder; Sergio Hofmeister de Almeida Martins Costa; José Geraldo Lopes Ramos; Edison Capp; Helena von Eye Corleta


Archive | 2008

Avaliação da relação da síndrome metabólica e a taxa de filtração glomerular (tfg) em pacientes com diabete melito tipo 2 (dm2)

Bittencourt Detanico; Renata Ortiz Pedrini; Letícia Schwerz Weinert; Eduardo Guimarães; Jorge Luiz Gross


Archive | 2008

Avaliação da função renal em pacientes com diabete melito tipo 2 (dm2) utilizando a fórmula do modification of diet in renal disease (mdrd) study

Renata Ortiz Pedrini; Ana Bittencourt Detanico; Letícia Schwerz Weinert; Eduardo Guimarães Camargo; Jorge Luiz Gross


Clinical & Biomedical Research | 2008

Cervico-mediastinal goiter with thyroid papillary microcarcinoma

Eduardo Guimarães Camargo; Ana Bittencourt Detanico; Renata Ortiz Pedrini; Sandra Pinho Silveiro


Archive | 2007

Avaliação da medida de cistatina c como marcador da taxa de filtração glomerular (TFG) em pacientes com diabete melito (DM) tipo 2

Ana Bittencourt Detanico; Renata Ortiz Pedrini; Letícia Schwerz Weinert; Eduardo Guimarães Camargo; Jorge Luiz Gross


Archive | 2007

Aspirina em baixa dose não altera a função renal de pacientes diabéticos tipo 2 microalbuminúricos em uso de enalapril

Renata Ortiz Pedrini; Letícia Schwerz Weinert; Eduardo Guimarães Camargo; Jorge Luiz Gross


Archive | 2007

Bócio cérvico-mediastinal compressivo com microcarcinoma papilífero da tireóide

Eduardo Guimarães Camargo; Ana Bittencourt Detanico; Renata Ortiz Pedrini; Sandra Pinho Silveiro


Archive | 2006

Expressão de proteína-quinase B (PKB) em músculo esquelético, adipócitos e placenta de gestantes com e sem pré-eclâmpsia

Renata Ortiz Pedrini; Pedro Salomão Piccinini; Rafael Bueno Orcy; Sabrina Schroeder; Sergio Hofmeister de Almeida Martins Costa; José Geraldo Lopes Ramos; Harald H. Klein; Wolfgang Schechinger; Helena von Eye Corleta

Collaboration


Dive into the Renata Ortiz Pedrini's collaboration.

Top Co-Authors

Avatar

Helena von Eye Corleta

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

José Geraldo Lopes Ramos

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Pedro Salomão Piccinini

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Rafael Bueno Orcy

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Eduardo Guimarães Camargo

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jorge Luiz Gross

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Letícia Schwerz Weinert

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Edison Capp

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Sandra Pinho Silveiro

Universidade Federal do Rio Grande do Sul

View shared research outputs
Researchain Logo
Decentralizing Knowledge